Increased CARVYKTI® manufacturing capacity with the physical expansion of the Raritan facility, now the largest cell therapy ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to turn its focus toward autoimmune diseases. The move isn’t shocking, as it ...

Akadeum Life Sciences, the leader in buoyant microbubble cell separation, today announced that its Chief Executive Officer Brandon McNaughton, PhD, will present at Biotech Showcase (TM) 2026 in San ...

Cell programming biotech bit.bio is slimming its workforce by 25% as the company pivots to focus on biomedical tools instead of therapeutics development. The decision was driven by “shifting market ...

Sana Biotechnology Inc. (NASDAQ:SANA) is one of the best emerging technology stocks to invest in. On December 8, Sana ...

NEW YORK – In an innovative move, a biotech company has found a new way of making stem cells without destroying embryos, touting it as a way to defuse one of the country’s fiercest political and ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells ...

Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies are working hard to make advancements that can help patients. Stem cells ...

K orea-based biotechnology company Nature Cell plans to open a manufacturing facility in Baltimore City, Maryland. The approximately 100,000-square-foot operation at the Gaslight Square mixed-use ...

Qihan Biotech Presents New Clinical Data on Allogeneic CAR-T Cell Therapies and Preclinical Data on In Vivo CAR-T at the American Society of Hematology (ASH) Annual Meeting – Clinical data from ...

With U.S. President Donald Trump’s tariffs, HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory ...